Global Cardiac Marker Market Size 2024, Forecast To 2033
6 Mar, 2024
The cardiac marker market size has grown rapidly in recent years. It will grow from $10.4 billion in 2023 to $11.55 billion in 2024 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to the increased incidence of cardiovascular diseases, the aging population and cardiovascular risk, awareness programs and health screenings, integration of biomarkers in clinical practice, and stringent regulatory standards and guidelines. The cardiac marker market size is expected to see rapid growth in the next few years. It will grow to $18.08 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to the rising burden of lifestyle-related diseases, remote monitoring and telemedicine, personalized medicine and precision diagnostics, point-of-care testing (POCT) adoption, collaborations, and partnerships in healthcare. Major trends in the forecast period include biomarker discovery and validation, personalized medicine approaches, technological advancements in assay platforms, integration of high-sensitivity troponin tests, and the rise in cardiovascular disease prevalence.
Global Cardiac Marker Market Key Driver
The rising prevalence of cardiac diseases is expected to propel the growth of the cardiac marker market going forward. Cardiac diseases are a group of conditions that affect the structure or operation of the heart and cause a range of medical problems. Cardiac markers are used to diagnose and monitor various cardiac conditions, including heart attacks, angina, heart failure, and other cardiovascular diseases. Thus, the demand for diagnostic tests or cardiac markers has increased. For instance, according to the British Heart Foundation, a cardiovascular research charity in the UK, in England, there were 30,000 more deaths from coronary heart disease from the start of the pandemic to August 2022. A record 346,000 persons were on a cardiac waiting list by the end of August 2022. Therefore, the rising prevalence of cardiac diseases will fuel the cardiac marker market's growth, with its market size in 2023 being there were 30,000 more deaths from coronary heart disease from the start of the pandemic to August 2022, and in 2024, a record 346,000 persons were on a cardiac waiting list by the end of August 2022.
Get A Free Sample Of The Global Cardiac Marker Market ReportGlobal Cardiac Marker Market Segments
The cardiac marker market covered in this report is segmented –
1) By Biomarker: Troponin, Creatine Kinase-MB (CK-MB), B-type Natriuretic Peptide (BNP), Myoglobin, Other Biomarkers
2) By Product: Reagent, Instrument, Chemiluminescence, Immunofluorescence, Immunochromatography, ELISA
3) By Indication: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Other Indications
4) By End User: Laboratory Testing Facilities, Hospital Labs, Reference Labs, Contract Testing Labs, Point-Of-Care Testing Facilities, Academic Institutions
By Geography:The regions covered in the cardiac marker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
North America was the largest region in the cardiac marker market in 2023. The regions covered in the cardiac marker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Cardiac Marker Industry Players
Abbott Laboratories Inc., Siemens AG, Danaher Corporation, BioMérieux SA, F. Hoffmann-La Roche AG, Beckman Coulter Inc., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Guangzhou Wondifo Biotech Co. Ltd., Creative Diagnostics, PerkinElmer Inc., Tosoh Corporation, Quidel Corporation, Randox Laboratories Ltd., Getinge Group, LSI Medience Corporation, Ortho Clinical Diagnostics, DiaSorin, Advanced Sterilization Products Services Inc., 3M Company, Belimed AG, Cantel Medical Corporation, MELAG Medizintechnik GmbH & Co. KG., Atom Medical Corporation, Bionet America Inc., Bistos Inc., CareFusion Corporation, Clinical Innovations LLC, Abcam plc, General Electric Company
Get The Full Global Cardiac Marker Market Report
Cardiac Marker Market Overview
Cardiac markers are biomolecules that are released into the bloodstream when there is damage or stress to the heart muscle. It is used to diagnose and monitor a variety of cardiac diseases, including heart attacks, angina, and heart failure.
Cardiac Marker Global Market Report 2023 provides data on the global cardiac marker market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The cardiac marker market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.